Skip to main content
. 2019 Oct 2;9:14197. doi: 10.1038/s41598-019-50732-w

Figure 4.

Figure 4

Treatment of A375-R cells with CDC7 inhibitor TAK-931 sensitizes resistant melanoma cells to Vemurafenib. (A) Cell proliferation assay for A375-R cells treated with either Vemurafenib (1.0 & 2.0 µM) or TAK-931 (50, 100 & 200 nM) or their combinations for 5 days. Cell cytotoxicity was assessed as indicated and expressed as a percentage of change. (B,C) Resistant cells were treated with increasing concentrations of Vemurafenib from 0 to 10 µM or TAK-931 inhibitor ranging from 0.0 to 1000 nM and monitored for 10 days. (D) Resistant cells were treated with low concentrations of TAK-931 (10, 25 and 50 nM), in the presence or absence of 1 µM Vemurafenib. The number of colonies was counted per each treatment as indicated and the statistical analysis was performed using one way ANOVA. Each bar represents the mean (%) ± SE of three replicates. NS: non-significant data. *Depicts significance at p < 0.05 relative to control cells (A–C) or to those cells individually treated with TAK-931 (D). ǂ,#Depicts significance relative to cells treated with 1 µM and 2 µM of Vemurafenib, respectively.